FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation

@article{Betts2013FGFR2HA,
  title={FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation},
  author={Guy N. J. Betts and Helen Valentine and Sue Pritchard and R. Swindell and Victoria M Williams and Shethah Morgan and Ewen A. Griffiths and Ian Shawn Welch and Catharine West and Christopher Womack},
  journal={Virchows Archiv},
  year={2013},
  volume={464},
  pages={145-156}
}
Receptor tyrosine kinase pathways are potential therapeutic targets in gastric adenocarcinoma patients. We evaluated HER2 and cMet protein expression, and FGFR2 gene amplification to assess their prognostic significance, and downstream mediators pS6 and pERK for their potential utility as pharmacodynamic biomarkers in patients with gastric adenocarcinoma. Tissue microarrays were constructed from resection samples of 184 patients who underwent surgery for gastric/gastro-oesophageal junction… CONTINUE READING
18 Citations
44 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 44 references

c-Met antibody LY2875358 (LA480) shows differential antitumor effects in non-small cell lung cancer

  • W Zeng, L Yan, +12 authors L Liu
  • Cancer Res
  • 2012
Highly Influential
1 Excerpt

Similar Papers

Loading similar papers…